MBiotech | UTM Institute for Management & Innovation
  • Newsfeed
    • Biopartnering Seminar Archive ♟︎ ♙
    • Octagon Health Data Science Competition ♙
  • Admissions
    • ♞ Admissions Requirements
    • ♞ Application Documents
    • ♞ How to Apply
    • ♞ Fees & Financial Assistance
    • ♞ Award Opportunities
    • ♞ Admission FAQ
    • ♞ Online Information Sessions
    • ♞ Stay Informed
  • Student Life
    • Courses for Winter 2023 ♙ ♟︎
    • Key Dates & Live Calendars ♟︎ ♙
    • BioPh Curriculum ♟︎
    • DHT Curriculum ♙
    • Our Electives ♘ ♜ ♖ ♕ ♝ ♗ ♚ ♔
    • The Chess Piece Metaphor
  • Research
    • Research News
    • MBiotech Student Projects
    • Research Faculty
  • Work Terms
    • Internships During COVID-19
    • Internship Partners
    • For Employers
    • For Students
    • BioPh Recruiting Timelines ♟︎
    • DHT Recruiting Timelines ♙
  • People
    • Meet Our Students
    • Alumni Profiles
  • About
    • MBiotech Overview
    • ♟︎ The Biopharmaceuticals stream
    • ♙ The Digital Health Technologies stream
    • 𐡸 MBiotech Classic
    • Current Opportunities
    • Contact Us
Clinical Trial Risk in Leukæmia: Biomarkers and Trial Design.

Clinical Trial Risk in Leukæmia: Biomarkers and Trial Design.

Research, Program News

Li AJ, Dhanraj JP, Lopes G, Parker JL. › Clinical Trial Risk in Leukæmia: Biomarkers and Trial Design. Hematological Oncology, 2021; 39(1):105-113. › 10.1002/hon.2818 Impact factor: 2·8 Alice Li ♙ lead author, Class of 2021 Jasper Dhanraj ♙ co-author, Class of 2021...
The Effect of Biomarker Use on the Speed and Duration of Clinical Trials for Cancer Drugs.

The Effect of Biomarker Use on the Speed and Duration of Clinical Trials for Cancer Drugs.

Research, Program News

Siddhi Manjrekar ♙Class of 2021 Luqmaan Mohamed, Siddhi Manjrekar, Derek P Ng, Alec Walsh, Gilberto Lopes, Jayson L Parker › The Effect of Biomarker Use on the Speed and Duration of Clinical Trials for Cancer Drugs The Oncologist, 2022, 27(10), 849-856›...
Does Biomarker Use in Oncology Improve Clinical Trial Failure Risk? A Large Scale Analysis.

Does Biomarker Use in Oncology Improve Clinical Trial Failure Risk? A Large Scale Analysis.

Research, Program News

Parker JL, Kuzulugil SS, Pereverzev K, Mac S, Lopes G, Shah Z, Weerasinghe A, Rubinger D, Falconi A, Bener A, Caglayan B, Tangri R & Mitsakakis N › Does Biomarker Use in Oncology Improve Clinical Trial Failure Risk? A Large-scale Analysis. Cancer Medicine, 2021;...

Recent Posts

  • Biopartnering Seminar Series · Strategic Positioning Plan for Eisai/Biogen’s Alzheimer’s Drug Lecanemab Following Aducanumab’s Controversy.
  • Biopartnering Seminar Series · PMPRB Guideline Amendments: Potential Solutions During a Time of Change for Novo Nordisk.
  • Biopartnering Seminar Series · Bridging the Efficacy Gap Between Clinical Data and Real World Evidence for Roche-Genentech Through Digital Solutions.
  • Biopartnering Seminar Series · Leveraging the Microbiome to Improve Entyvio’s Market Share.
  • Biopartnering Seminar Series · Biogen Whistleblower Settlement: Solutions to Maintain Leading Reputation.

Recent Comments

No comments to show.
University of Toronto Mississauga
3359 Mississauga Road
Mississauga, ON, L5L 1C6
(905) 569-4455
  • Follow
  • Follow
  • Follow
  • Follow
UTM centered on a map
 

Font Loader
Defy Gravity

Accessibility | Privacy | Contact UTM

© 2019 – 2021 University of Toronto Mississauga